Muhammad Azam, MD
Family Medicine · El Cajon, CANPI 1740244367
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (56.2%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Daiichi Sankyo Inc. accounts for 75.2% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2019 at $16,052 and has fallen 95.3% since, to $751 in 2025. Among family medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 260 payments — averaging $107.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$21K
- Biohaven Pharmaceutical Holding Company Ltd.$2K
- AbbVie$1K
- AstraZeneca$801
- Lilly USA, LLC$737
- GSK$310
- plus $2K from 27 others
Across 2 payments — averaging $34,752 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$70K
What the payments were for
- Consulting fees$6,51323%
- Travel & lodging$15,74156%
- Food & beverage$5,70120%
- Education$490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 18 | $21,071 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $1,980 |
| AbbVie(2 entities) | 59 | $1,199 |
| AstraZeneca | 35 | $801 |
| Lilly USA, LLC | 38 | $737 |
| GSK | 14 | $310 |
| Boehringer Ingelheim | 11 | $263 |
| Nestle Healthcare Nutrition Inc. | 10 | $195 |
| Novo Nordisk | 7 | $168 |
| Pfizer | 7 | $156 |
| Merck | 5 | $140 |
| Astellas Pharma US Inc | 5 | $107 |
| Novartis | 5 | $89 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $78 |
| Edwards Lifesciences | 2 | $74 |
| Bayer | 3 | $71 |
| Xeris Pharmaceuticals, Inc. | 3 | $70 |
| Sunovion Pharmaceuticals Inc. | 5 | $60 |
| Teva Pharmaceuticals USA, Inc. | 3 | $60 |
| Kowa Pharmaceuticals America, Inc. | 2 | $49 |
| Bausch Health US, LLC | 2 | $44 |
| Amgen | 2 | $38 |
| Amarin Pharma, Inc. | 2 | $32 |
| Impulse Dynamics (USA) Inc. | 1 | $27 |
| Dexcom, Inc. | 1 | $25 |
| Johnson & Johnson | 1 | $23 |
| Mannkind Corporation | 1 | $23 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| Corcept Therapeutics | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Metacel Pharmaceuticals LLC | 1 | $18 |
| Eisai Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,807
- FARXIGA$111
How this compares
$28,004 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 116 | $106,217 |
| MounjaroTirzepatide | 90 | $101,229 |
| CreonLipase/Protease/Amylase | 15 | $52,549 |
| RybelsusSemaglutide | 43 | $43,289 |
| EliquisApixaban | 58 | $41,946 |
| XareltoRivaroxaban | 44 | $41,669 |
| LinzessLinaclotide | 55 | $36,663 |
| OzempicSemaglutide | 33 | $31,360 |
| DescovyEmtricitabine/Tenofov Alafenam | 13 | $27,591 |
| VascepaIcosapent Ethyl | 94 | $26,696 |
| JanuviaSitagliptin Phosphate | 24 | $24,718 |
| TrulicityDulaglutide | 25 | $23,876 |
| MyrbetriqMirabegron | 24 | $19,482 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $19,232 |
| FarxigaDapagliflozin Propanediol | 27 | $18,360 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $737 | $125,105115 claims |
| Boehringer IngelheimJardiance | $263 | $106,217116 claims |
| AbbVieCreon, Linzess, Qulipta, Synthroid | $1,199 | $101,612103 claims |
| Novo NordiskRybelsus, Ozempic | $168 | $74,64976 claims |
| PfizerEliquis | $156 | $41,94658 claims |
| Johnson & JohnsonXarelto | $23 | $41,66944 claims |
| AstraZenecaFarxiga, Brilinta | $801 | $32,44948 claims |
| MerckJanuvia | $140 | $24,71824 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $310 | $23,23939 claims |
| Astellas Pharma US IncMyrbetriq | $107 | $19,48224 claims |
| BayerKerendia | $71 | $15,30415 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $49 | $7,09712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in El Cajon
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
- Amira AyadBakersfield$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.